April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived at a significantly higher rate when treated with a protocol using the ...
Cardiogenic Shock
This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.
-
-
William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, explains final data from the National Cardiogenic Shock Initiative Study (NCSI), The ...
-
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass ...
-
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the company is working on and highlighted hemodynamic presentations at the 2020 ...
Feature | Cardiogenic Shock | By Dave Fornell, Editor
April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived ...
April 29, 2021
William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...
April 28, 2021
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one ...
October 26, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...
October 20, 2020
August 3, 2020 — A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart ...
August 03, 2020
Navin Kapur, M.D., FAHA, FACC, FSCAI, director, Acute Mechanical Circulatory Support Program and executive director of ...
July 15, 2020
In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure or ...
June 30, 2020
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor
It was originally thought novel coronavirus (COVID-19, SARS-CoV-2) was primarily a respiratory disorder, but as larger ...
June 05, 2020
This is a quick animation demonstrating how the new 9 French Abiomed Impella ECP expands to approximately 18 French and ...
June 05, 2020
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor
A new, serious COVID-19 cardiovascular presentation emerged in late April and early May 2020 in the form of pediatric ...
May 20, 2020
May 1, 2020 — Abiomed, maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal ...
May 01, 2020
April 23, 2020 – LivaNova PLC said the U.S. Food and Drug Administration (FDA) is now permitting the company to expand ...
April 23, 2020
Gallery | Hemodynamic Support Devices | Dave Fornell, Editor
DAIC Editor Dave Fornell recently took a tour of the Abiomed Impella production line at its headquarters in Danvers ...
February 10, 2020
Navin Kapur, M.D., FAHA, FACC, FSCAI, director, Acute Mechanical Circulatory Support Program and executive director of ...
January 24, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant ...
January 09, 2020© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now